 Sarit Polsky
Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy in Diabetics | 25 | 2025 | 120 | 13.670 |
Why?
| | Diabetes Mellitus, Type 1 | 53 | 2026 | 3842 | 6.930 |
Why?
| | Insulin Infusion Systems | 20 | 2025 | 477 | 6.200 |
Why?
| | Blood Glucose Self-Monitoring | 32 | 2025 | 699 | 6.000 |
Why?
| | Blood Glucose | 41 | 2025 | 2312 | 5.490 |
Why?
| | Hypoglycemic Agents | 22 | 2025 | 1379 | 4.900 |
Why?
| | Insulin | 23 | 2025 | 2501 | 4.020 |
Why?
| | Pregnancy | 34 | 2025 | 7180 | 2.130 |
Why?
| | Diabetes, Gestational | 7 | 2025 | 321 | 1.720 |
Why?
| | Hypoglycemia | 8 | 2025 | 477 | 1.540 |
Why?
| | Pregnancy Outcome | 11 | 2025 | 476 | 1.340 |
Why?
| | Diabetic Ketoacidosis | 4 | 2025 | 209 | 1.190 |
Why?
| | Female | 58 | 2026 | 77976 | 0.930 |
Why?
| | Ketones | 1 | 2025 | 53 | 0.870 |
Why?
| | Alcohol Drinking | 4 | 2020 | 812 | 0.810 |
Why?
| | Adult | 41 | 2026 | 40262 | 0.790 |
Why?
| | Postnatal Care | 2 | 2021 | 72 | 0.760 |
Why?
| | Humans | 70 | 2026 | 144261 | 0.720 |
Why?
| | Diabetes Mellitus, Type 2 | 9 | 2025 | 2516 | 0.680 |
Why?
| | Diabetes Complications | 2 | 2020 | 220 | 0.660 |
Why?
| | Preconception Care | 1 | 2021 | 50 | 0.650 |
Why?
| | Pilot Projects | 6 | 2024 | 1867 | 0.640 |
Why?
| | Young Adult | 19 | 2026 | 13990 | 0.580 |
Why?
| | Spices | 2 | 2014 | 6 | 0.540 |
Why?
| | Tobacco Use | 1 | 2018 | 61 | 0.540 |
Why?
| | Hyperglycemia | 4 | 2022 | 374 | 0.500 |
Why?
| | Postprandial Period | 2 | 2019 | 115 | 0.490 |
Why?
| | Food Preferences | 2 | 2014 | 126 | 0.490 |
Why?
| | Fear | 1 | 2019 | 366 | 0.480 |
Why?
| | Quality of Life | 3 | 2025 | 3166 | 0.460 |
Why?
| | Obesity | 5 | 2019 | 3057 | 0.440 |
Why?
| | Lunch | 1 | 2014 | 8 | 0.430 |
Why?
| | Meat Products | 1 | 2014 | 27 | 0.430 |
Why?
| | Breakfast | 1 | 2014 | 20 | 0.430 |
Why?
| | Cardiovascular Diseases | 5 | 2024 | 2134 | 0.410 |
Why?
| | Postoperative Care | 1 | 2015 | 288 | 0.380 |
Why?
| | Insulin Resistance | 3 | 2022 | 1232 | 0.370 |
Why?
| | Preoperative Care | 1 | 2015 | 379 | 0.360 |
Why?
| | Diabetes Mellitus | 3 | 2021 | 1092 | 0.360 |
Why?
| | Infant, Newborn | 5 | 2024 | 6424 | 0.360 |
Why?
| | Hypertension | 1 | 2020 | 1254 | 0.360 |
Why?
| | Diabetic Nephropathies | 3 | 2020 | 314 | 0.350 |
Why?
| | Comorbidity | 2 | 2021 | 1646 | 0.350 |
Why?
| | Bariatric Surgery | 1 | 2015 | 236 | 0.340 |
Why?
| | Retrospective Studies | 13 | 2026 | 17009 | 0.340 |
Why?
| | Insulin Aspart | 2 | 2022 | 30 | 0.340 |
Why?
| | Uric Acid | 3 | 2022 | 166 | 0.330 |
Why?
| | Postpartum Period | 2 | 2025 | 361 | 0.320 |
Why?
| | Weight Loss | 4 | 2019 | 832 | 0.310 |
Why?
| | Diabetic Neuropathies | 2 | 2022 | 97 | 0.310 |
Why?
| | Allopurinol | 2 | 2020 | 69 | 0.310 |
Why?
| | Glomerular Filtration Rate | 4 | 2022 | 758 | 0.300 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 1054 | 0.300 |
Why?
| | Monitoring, Physiologic | 2 | 2025 | 289 | 0.300 |
Why?
| | Feeding Behavior | 1 | 2014 | 681 | 0.280 |
Why?
| | Prediabetic State | 1 | 2011 | 243 | 0.260 |
Why?
| | Cross-Over Studies | 3 | 2024 | 600 | 0.250 |
Why?
| | Prenatal Care | 2 | 2021 | 306 | 0.240 |
Why?
| | Middle Aged | 22 | 2026 | 35762 | 0.240 |
Why?
| | Gastric Bypass | 2 | 2019 | 124 | 0.230 |
Why?
| | Feasibility Studies | 2 | 2024 | 1087 | 0.220 |
Why?
| | United States | 9 | 2024 | 15876 | 0.220 |
Why?
| | Risk Factors | 10 | 2022 | 10699 | 0.220 |
Why?
| | Cost Savings | 1 | 2024 | 86 | 0.210 |
Why?
| | Pancreas, Artificial | 3 | 2025 | 97 | 0.210 |
Why?
| | Labor, Obstetric | 1 | 2024 | 66 | 0.200 |
Why?
| | Hospitalization | 3 | 2024 | 2424 | 0.200 |
Why?
| | Weight Reduction Programs | 2 | 2015 | 135 | 0.200 |
Why?
| | Single-Blind Method | 1 | 2024 | 311 | 0.190 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 160 | 0.190 |
Why?
| | Biomedical Technology | 1 | 2023 | 49 | 0.190 |
Why?
| | Male | 24 | 2026 | 72035 | 0.190 |
Why?
| | Off-Label Use | 1 | 2023 | 48 | 0.190 |
Why?
| | Registries | 4 | 2020 | 2382 | 0.190 |
Why?
| | Insulin Lispro | 1 | 2022 | 42 | 0.190 |
Why?
| | Patient Admission | 1 | 2024 | 218 | 0.180 |
Why?
| | Aged | 15 | 2026 | 25850 | 0.180 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 19 | 0.180 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2022 | 32 | 0.180 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 623 | 0.180 |
Why?
| | Insulins | 1 | 2022 | 38 | 0.170 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 279 | 0.170 |
Why?
| | Diabetic Retinopathy | 1 | 2024 | 207 | 0.170 |
Why?
| | Adolescent | 11 | 2026 | 22281 | 0.170 |
Why?
| | Technology | 1 | 2021 | 95 | 0.170 |
Why?
| | Vitamin D Deficiency | 1 | 2022 | 185 | 0.160 |
Why?
| | Parity | 1 | 2020 | 109 | 0.160 |
Why?
| | Patient Satisfaction | 1 | 2025 | 704 | 0.160 |
Why?
| | Xanthine Oxidase | 1 | 2020 | 79 | 0.160 |
Why?
| | Islets of Langerhans | 1 | 2026 | 832 | 0.150 |
Why?
| | Overweight | 2 | 2015 | 606 | 0.150 |
Why?
| | Epidemics | 1 | 2021 | 98 | 0.150 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 28 | 0.150 |
Why?
| | Appetite Regulation | 1 | 2019 | 31 | 0.150 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2926 | 0.140 |
Why?
| | Diet, Reducing | 1 | 2019 | 91 | 0.140 |
Why?
| | Autoantibodies | 1 | 2026 | 1497 | 0.140 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 206 | 0.140 |
Why?
| | Eczema | 1 | 2018 | 66 | 0.130 |
Why?
| | Telemetry | 1 | 2017 | 41 | 0.130 |
Why?
| | Algorithms | 1 | 2025 | 1834 | 0.130 |
Why?
| | Treatment Outcome | 4 | 2021 | 11643 | 0.130 |
Why?
| | Insulin, Short-Acting | 1 | 2016 | 8 | 0.120 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 824 | 0.120 |
Why?
| | Sleep | 1 | 2024 | 901 | 0.120 |
Why?
| | Double-Blind Method | 4 | 2024 | 2025 | 0.120 |
Why?
| | Infusions, Subcutaneous | 1 | 2016 | 24 | 0.120 |
Why?
| | Glucose | 1 | 2021 | 1046 | 0.120 |
Why?
| | HIV Infections | 1 | 2011 | 3079 | 0.110 |
Why?
| | Self Care | 1 | 2018 | 388 | 0.110 |
Why?
| | Sex Characteristics | 2 | 2018 | 789 | 0.110 |
Why?
| | Albuminuria | 3 | 2022 | 187 | 0.110 |
Why?
| | Taste | 2 | 2014 | 239 | 0.110 |
Why?
| | Cheese | 1 | 2014 | 7 | 0.110 |
Why?
| | Gastroplasty | 1 | 2014 | 32 | 0.110 |
Why?
| | Body Mass Index | 3 | 2019 | 2420 | 0.110 |
Why?
| | Pleasure | 1 | 2014 | 17 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2019 | 1705 | 0.100 |
Why?
| | Chickens | 1 | 2014 | 191 | 0.100 |
Why?
| | Life Style | 2 | 2023 | 475 | 0.100 |
Why?
| | Disease Management | 1 | 2018 | 643 | 0.100 |
Why?
| | Vegetables | 1 | 2014 | 170 | 0.100 |
Why?
| | Skin | 1 | 2018 | 754 | 0.100 |
Why?
| | Delphi Technique | 1 | 2015 | 329 | 0.100 |
Why?
| | Models, Organizational | 1 | 2013 | 143 | 0.090 |
Why?
| | Menopause | 1 | 2016 | 319 | 0.090 |
Why?
| | Community Health Services | 1 | 2014 | 232 | 0.090 |
Why?
| | Program Evaluation | 2 | 2014 | 946 | 0.090 |
Why?
| | Glucose Tolerance Test | 2 | 2011 | 360 | 0.090 |
Why?
| | Dietary Fats | 1 | 2014 | 313 | 0.090 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5813 | 0.080 |
Why?
| | Cohort Studies | 3 | 2020 | 5935 | 0.080 |
Why?
| | Internet | 1 | 2016 | 698 | 0.080 |
Why?
| | Child | 7 | 2026 | 22537 | 0.080 |
Why?
| | Creatinine | 2 | 2022 | 505 | 0.080 |
Why?
| | Laparoscopy | 1 | 2014 | 475 | 0.080 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2022 | 145 | 0.080 |
Why?
| | Renin-Angiotensin System | 2 | 2020 | 78 | 0.070 |
Why?
| | Risk Assessment | 1 | 2017 | 3637 | 0.070 |
Why?
| | Aged, 80 and over | 5 | 2021 | 8243 | 0.070 |
Why?
| | Diabetic Angiopathies | 2 | 2020 | 254 | 0.060 |
Why?
| | Telemedicine | 1 | 2016 | 940 | 0.060 |
Why?
| | Delivery of Health Care | 1 | 2013 | 940 | 0.060 |
Why?
| | Diet | 1 | 2014 | 1271 | 0.060 |
Why?
| | Zinc Transporter 8 | 1 | 2026 | 70 | 0.060 |
Why?
| | Rural Health Services | 1 | 2007 | 141 | 0.060 |
Why?
| | Metformin | 1 | 2009 | 315 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6021 | 0.060 |
Why?
| | Age of Onset | 1 | 2026 | 536 | 0.050 |
Why?
| | Health Behavior | 1 | 2009 | 782 | 0.050 |
Why?
| | Actigraphy | 1 | 2024 | 145 | 0.050 |
Why?
| | Bionics | 1 | 2022 | 14 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1682 | 0.050 |
Why?
| | Iohexol | 1 | 2022 | 23 | 0.050 |
Why?
| | Bromocriptine | 1 | 2022 | 31 | 0.050 |
Why?
| | Energy Intake | 2 | 2019 | 499 | 0.040 |
Why?
| | Prognosis | 2 | 2021 | 4278 | 0.040 |
Why?
| | Demography | 1 | 2021 | 284 | 0.040 |
Why?
| | Aspirin | 1 | 2023 | 399 | 0.040 |
Why?
| | Peptide YY | 1 | 2019 | 24 | 0.040 |
Why?
| | Satiation | 1 | 2019 | 28 | 0.040 |
Why?
| | Vascular Stiffness | 1 | 2024 | 462 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 363 | 0.040 |
Why?
| | Ghrelin | 1 | 2019 | 38 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2023 | 509 | 0.040 |
Why?
| | Wounds and Injuries | 1 | 2007 | 952 | 0.040 |
Why?
| | Appetite | 1 | 2019 | 69 | 0.040 |
Why?
| | Sex Factors | 2 | 2018 | 2096 | 0.030 |
Why?
| | Income | 1 | 2019 | 199 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5389 | 0.030 |
Why?
| | Population Surveillance | 1 | 2021 | 483 | 0.030 |
Why?
| | Lipids | 1 | 2022 | 700 | 0.030 |
Why?
| | Educational Status | 1 | 2019 | 464 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 355 | 0.030 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2016 | 117 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2021 | 688 | 0.030 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 162 | 0.030 |
Why?
| | Medicare | 1 | 2021 | 881 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 574 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1495 | 0.030 |
Why?
| | Meals | 1 | 2014 | 130 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3403 | 0.020 |
Why?
| | Blood Pressure | 1 | 2019 | 1759 | 0.020 |
Why?
| | Animals | 1 | 2014 | 38030 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3313 | 0.020 |
Why?
| | Focus Groups | 1 | 2014 | 569 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2840 | 0.020 |
Why?
| | Health Education | 1 | 2014 | 357 | 0.020 |
Why?
| | Obesity, Morbid | 1 | 2014 | 275 | 0.020 |
Why?
| | Social Support | 1 | 2014 | 649 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 2088 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 192 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4254 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2009 | 194 | 0.020 |
Why?
| | Glucose Intolerance | 1 | 2009 | 142 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 7970 | 0.020 |
Why?
| | Kenya | 1 | 2007 | 129 | 0.020 |
Why?
| | Accidental Falls | 1 | 2007 | 222 | 0.010 |
Why?
| | Colorado | 1 | 2014 | 4562 | 0.010 |
Why?
| | Time Factors | 1 | 2015 | 7155 | 0.010 |
Why?
| | Violence | 1 | 2007 | 280 | 0.010 |
Why?
| | Incidence | 1 | 2009 | 2870 | 0.010 |
Why?
| | Burns | 1 | 2007 | 376 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2014 | 2916 | 0.010 |
Why?
|
|
Polsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|